EGFR (also known ErbB1 or HER1) is overexpressed in 15%–30% of all BCs, most frequently in the aggressive triple-negative BCs (TNBCs) and inflammatory BCs, and it is also associated with large tumor size, poor differentiation, and poor clinical outcomes for these tumor types (5). Here, EGFR is linked to neoplasm.